About the Developmental Therapeutics Program
Founded in 1994, the Developmental Therapeutics Program focuses on the development of new agents, and we work closely with the Pediatric Center for Personal Cancer Genomics and Therapeutics to identify personalized therapies for children with cancer.
Members of the program include physicians board-certified in pediatric hematology-oncology, clinical pharmacology, hospice and palliative medicine, as well as post-doctoral fellows, clinical research nurses, nurse practitioners, data managers and laboratory research associates. Program investigators have developed and led numerous national early phase and pharmacokinetic studies, and they also have expertise in pharmacokinetic-pharmacodynamic modeling including population pharmacokinetics.
We view referring physicians as partners in care, and keep them informed throughout the entire process of referral, evaluation, diagnosis, treatment and follow-up.
We participate in every major pediatric oncology and pharmacology cooperative group, providing our patients access to cutting-edge therapy for pediatric malignancies. Our program is a major contributor to the Children’s Oncology Group (COG) Phase I Consortium and is the only COG Phase 1 institution in the southwestern United States. In addition, we are one of only three Alex’s Lemonade Stand Developmental Therapeutics Centers of Excellence in the nation. As leading researchers, our physicians develop nationwide studies for the COG and the Pediatric Brain Tumor Consortium. We also work closely with industry to make important new agents available for children with cancer.
The Developmental Therapeutics Program offers Phase 1 and other early phase clinical trials for a wide range of children’s cancers. We work closely with referring physicians and families to identify appropriate options for each individual child and to support the child and the whole family through the entire treatment process.